Evidence map›Paper›PMID 28039611›Full record

ArticleMolecular and cellular biochemistry2017

Alternative new mesenchymal stem cell source exerts tumor tropism through ALCAM and N-cadherin via regulation of microRNA-192 and -218.

Ran Kim, Sang In Park, Chang Youn Lee, Jihyun Lee, Pilseog Kim, Sekyung Oh, Hojin Lee, Min Young Lee, Jongmin Kim, Yong-An Chung and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 2 countries.

Ran KimDepartment of Biology Education, College of Education, Pusan National University, Pusan, 609-735, South Korea.
Sang In ParkInstitute of Catholic Integrative Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Incheon, 403-720, South Korea.
Chang Youn LeeBrain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 120-752, South Korea.
Jihyun LeeDepartment of Biology Education, College of Education, Pusan National University, Pusan, 609-735, South Korea.
Pilseog KimDepartment of Biology Education, College of Education, Pusan National University, Pusan, 609-735, South Korea.
Sekyung OhDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Hojin LeeDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.
Min Young LeeDepartment of Molecular Physiology, College of Pharmacy, Kyungpook National University, Daegu, 702-701, South Korea.
Jongmin KimDepartment of Life Systems, Sookmyung Women's University, 52 Hyochangwon-gil, Seoul, 140-742, South Korea.
Yong-An ChungInstitute of Catholic Integrative Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Incheon, 403-720, South Korea.
Ki-Chul HwangInstitute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangwon-do, 210-701, South Korea.
Lee-So MaengInstitute of Catholic Integrative Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Incheon, 403-720, South Korea. mls1004@catholic.ac.kr.
Woochul ChangDepartment of Biology Education, College of Education, Pusan National University, Pusan, 609-735, South Korea. wchang1975@pusan.ac.kr.
Pusan National University · KRCatholic University of Korea · KRCatholic Kwandong University · KRIncheon St. Mary's Hospital · KRKyungpook National University · KRSookmyung Women's University · KRStanford University · USYale University · USYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are the most common type of malignant primary brain tumors. Some treatments of gliomas exist, but they are rarely curative. Mesenchymal stem cells (MSCs) are emerging as potential modes of targeted cancer therapy owing to their capacity for homing toward tumor sites. It has been proposed that MSCs derived from various sources, such as bone marrow, adipose tissue and umbilical cord blood, can be used as cell-based therapy for brain tumors. Here, MSCs obtained from the synovial fluid of osteoarthritis or rheumatoid arthritis patients were investigated as therapeutic candidates. Specifically, we compared migratory and adhesive abilities, as well as expression levels of related genes and microRNA in bone marrow derived-MSCs (BMMSCs), adipose derived-MSCs (ADMSCs), and synovial fluid derived-MSCs (SFMSCs) after treatment with conditioned medium from gliomas. Migration and adhesion of SFMSCs increased through upregulation of the activated lymphocyte cell adhesion molecule (ALCAM) and N-cadherin by microRNA-192 and -218 downregulation, similar to BMMSCs and ADMSCs. Migratory capacities of all types of MSCs were evaluated in vivo, and SFMSCs migrated intensively toward gliomas. These results suggest that SFMSCs have potential for use in cell-based antitumor therapies.

Indexed as

Cell MovementActivated-Leukocyte Cell Adhesion MoleculeAntigens, CDBrain NeoplasmsCadherinsCell Adhesion Molecules, NeuronalCell Line, TumorFemaleFetal ProteinsGliomaHumansMaleMesenchymal Stem CellsMicroRNAsActivated-Leukocyte Cell Adhesion MoleculeALCAM protein, humanAntigens, CDCadherinsCDH2 protein, humanCell Adhesion Molecules, NeuronalFetal ProteinsMicroRNAsMIRN192 microRNA, humanMIRN218 microRNA, humanActivated lymphocyte cell adhesion moleculemicroRNA-192microRNA-218N-CadherinSynovial fluid derived-mesenchymal stem cellsTumor tropism

Identifiers

PMID28039611
PMCPMC5306073
OpenAlexW2567114058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.